Comparative Advantage of China and India in the Outsourcing Services for Biomedical Research and Dev

来源 :中国上海第七届国际新药发明科技年会 | 被引量 : 0次 | 上传用户:toerrisme
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Both China and India are increasingly major players in the area of CRO services for the global pharmaceutical and biotechnology industry.This presentation intends to share information on various segments of the CRO service chain,such as discovery chemistry,preclinical services,clinical trial services,manufacturing of API and finished products,etc.A SWOT (strength,weakness,opportunity,and threat) analysis will be provided on China and India in regards to government policy,regulatory environment,talents,infrastructure,cost structure,etc.
其他文献
Purpose:Advanced,castration-resistant prostate cancer,for which there are few treatment options,remains one of the leading causes of cancer death.MicroRNAs (miRNAs) have provided a new opportunity for
会议
MicroRNAs (miRNAs) contains 18-24 nucleotides,which are often linked as clusters transcribed from genomic DNAs.The miR-17~92 is the most extensively studied cluster.This cluster and its paralogs play
会议
Schistosomiasis causes liver and intestinal damage and can be very debilitating.The pairing of a male worm with a female worm residing in the gynaecophoral canal of male plays a critical role in the d
会议
A live cell profiling approach for real-time monitoring and profiling of small molecules compounds will be described.The non-invasive readout allows continuous monitoring of cells inside the wells pro
会议
Up-regulation ofproinflammatory cytokines by activated macrophages (Mψ) has been shown to drive the pathogenesis of several rheumatic diseases including rheumatoid arthritis,chronic plaque psoriasis,a
会议
1.Opportunity.Pharmaceutical markets development have slowed to 2.5%-3.5%; and revenue growth is softening most in those countries where a high portion of drug costs are self-paid,such as the U.S.,Chi
会议
Current pre-clinical cancer animal models are poorly predictive in clinical efficacy,and have limited value in predicting disease indications in humans.Primary tumor tissue offers a valuable resource
会议
Dr.Jing-Shan Hu is currently Director of Licensing & External Research (Mainland China,Hong Kong,& Taiwan) at Merck & Co.,Inc.,USA.She is responsible for identifying and developing opportunities relat
会议
The challenges for pharmaceutical and biotech companies are to discover and develop innovative and effective therapeutics at a lesser cost with the shorter timeframes.Contract research and partnership
会议
The field of translational medicine and translational pharmacology centers around the desire to understand the linkage between molecular modulation and pharmacologic effect.In vitro studies provide a
会议